Y-mAbs Therapeutics Inc (OQ:YMAB)

Business Focus: Bio Therapeutic Drugs

Mar 14, 2024 09:05 am ET

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the...

Mar 04, 2024 07:30 am ET

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Feb 29, 2024 04:05 pm ET

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Feb 16, 2024 07:30 am ET

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S....

Jan 02, 2024 04:05 pm ET

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023 04:05 pm ET

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today...

Nov 13, 2023 04:05 pm ET

Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today...

Oct 31, 2023 07:05 am ET

Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the U.S. financial...

Oct 23, 2023 05:45 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ:

Levi & Korsinsky announces that it has commenced an investigation of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) concerning possible breaches of fiduciary duty. To obtain additional information, go to:...

Oct 18, 2023 04:05 pm ET

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced...

Oct 17, 2023 04:05 pm ET

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today...

Oct 16, 2023 04:05 pm ET

Y-mAbs Announces Publication in Cancers

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today...

Sep 21, 2023 06:57 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ:

NEW YORK, Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) concerning possible breaches of fiduciary duty. To obtain additional information, go to:

Sep 21, 2023 04:05 pm ET

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today...

Sep 06, 2023 04:05 pm ET

Y-mAbs to Participate at Upcoming Investor Conferences in September

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today...

Aug 10, 2023 04:05 pm ET

Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today...

Aug 02, 2023 04:05 pm ET

Y-mAbs to Participate at Upcoming Investor Conferences

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today...

Aug 01, 2023 04:05 pm ET

Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the U.S. financial markets....

May 26, 2023 09:00 am ET

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

May 26, 2023 09:00 am ET

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

May 23, 2023 09:00 am ET

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

May 08, 2023 04:01 pm ET

Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

Apr 28, 2023 09:00 am ET

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financial markets. The...

Apr 18, 2023 09:00 am ET

Y-mAbs Announces Presentation of Naxitamab data at AACR

Apr 05, 2023 09:00 am ET

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

Mar 30, 2023 04:01 pm ET

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

Mar 30, 2023 12:03 pm ET

Lifshitz Law PLLC Announces Investigations of Sotera Health Co. (NASDAQ: SHC), Fate Therapeutics, Inc. (NASDAQ: FATE), Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), and International Business Machines Cor

Sotera Health Co. (NASDAQ: SHC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company’s made false and misleading representations...

Mar 21, 2023 04:01 pm ET

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, 2022, on Thursday, March 30, 2023, after the close of the U.S. financial markets. The...

Mar 20, 2023 12:05 pm ET

DEADLINE ALERT for YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Mar 20, 2023 05:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK, March 20, 2023 /PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders:

Mar 18, 2023 07:00 am ET

Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

NEW YORK, March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) and reminds investors of the March 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Mar 17, 2023 08:00 pm ET

Y-MABS THERAPEUTICS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 20, 2023 to file lead plaintiff applications in a securities class action lawsuit against Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company’s securities between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Mar 17, 2023 04:19 pm ET

Y-mAbs Therapeutics, Inc.: Please contact the Portnoy Law Firm to recover your losses; March 20, 2023 deadline

The Portnoy Law Firm advises Y-mAbs Therapeutics, Inc. (“Y-mAbs” or “the Company”) (NASDAQ: YMAB) investors that a lawsuit filed on behalf of investors that purchased Y-mAbs securities (NASDAQ: YMAB October 6, 2020 and October 28, 2022, inclusive...

Mar 17, 2023 11:20 am ET

YMAB FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 20 Deadline in Securitie

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) between October 6, 2020 and October 28, 2022, both dates inclusive (the “Class Period”), of the important March...

Mar 17, 2023 10:00 am ET

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

The Law Offices of Frank R. Cruz reminds investors of the upcoming March 20, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ:

Mar 17, 2023 05:45 am ET

YMAB SHAREHOLDER ALERT: Jakubowitz Law Reminds Y-mAbs Shareholders of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK, March 17, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB).

Mar 16, 2023 12:17 pm ET

YMAB 4-DAY DEADLINE ALERT: Hagens Berman Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys Before Mar. 20th Deadline in Securities Fraud Class Action

Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now. Class Period: Oct. 6, 2020 – Oct. 28, 2022Lead Plaintiff Deadline: Mar. 20, 2023Visit:...

Mar 16, 2023 05:45 am ET

YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, March 16, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities lawsuit.

Mar 15, 2023 10:50 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Y-mAbs Therapeutics, Inc. - YMAB

The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company’s securities between October 6, 2020 and October 28, 2022, inclusive (the “Class...

Mar 15, 2023 06:05 pm ET

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or "the Company") (NASDAQ:YMAB) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Mar 15, 2023 05:30 pm ET

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 20 Deadline in Securities Class Action - YMAB

NEW YORK, March 15, 2023 /PRNewswire/ --

Mar 15, 2023 10:00 am ET

YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit

BENSALEM, Pa., March 15, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB).

Mar 15, 2023 05:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Y-mAbs Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 20, 2023 - (NASDAQ: YMAB)

NEW YORK, March 15, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Y-mAbs Therapeutics, Inc..

Mar 15, 2023 01:45 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Did you lose money on investments in Y-mAbs Therapeutics? If so, please visit Y-mAbs Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.

Mar 14, 2023 10:31 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 20, 2023 to file lead plaintiff applications in a securities class action lawsuit against Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they...

Mar 14, 2023 08:48 pm ET

DEADLINE ALERT for YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Mar 14, 2023 05:45 am ET

YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on Behalf of Y-mAbs Therapeutics, Inc. Shareholders

NEW YORK, March 14, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) alleging that the Company violated federal securities laws.

Mar 13, 2023 07:15 pm ET

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or "the Company") (NASDAQ:YMAB) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereu

Mar 13, 2023 06:45 pm ET

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Mar 13, 2023 04:35 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

NEW YORK, March 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Mar 13, 2023 12:24 pm ET

DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Mar 13, 2023 11:00 am ET

Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Y-mAbs securities between October 6, 2020 and October 28, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:

Mar 13, 2023 09:30 am ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 20, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Y-mAbs Therapeutics, Inc. (“Y-mAbs”...

Mar 13, 2023 05:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK, March 13, 2023 /PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders:

Mar 13, 2023 01:45 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...

Mar 12, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Fate Therapeutics, Inc. (NASDAQ:...

Mar 11, 2023 03:49 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys Before Mar. 20th Deadline in Securities Fraud Class Action

Mar 11, 2023 06:00 am ET

Y-MABS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Opt

NEW YORK, March 11, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) and reminds investors of the March 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Mar 10, 2023 09:50 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB

NEW ORLEANS, March 10, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 20, 2023 to file lead plaintiff applications in a securities class action lawsuit against Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company's securities between October 6, 2020 and October 28, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

Mar 10, 2023 02:14 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....

Mar 10, 2023 12:00 pm ET

Y-mAbs Therapeutics, Inc.: Please contact the Portnoy Law Firm to recover your losses; March 20, 2023 deadline

Mar 10, 2023 10:00 am ET

YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Mar 09, 2023 08:00 am ET

YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit

LOS ANGELES , March 9, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB).

Mar 09, 2023 04:45 am ET

YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, March 9, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities lawsuit.

Mar 08, 2023 09:50 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Y-mAbs Therapeutics, Inc. - YMAB

CEDARHURST, N.Y., March 8, 2023 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company's securities between October 6, 2020 and October 28, 2022, inclusive (the "Class Period"), including shares of Rodgers Silicon prior to July 15, 2021. Shareholders have until March 20, 2023 to file lead plaintiff applications in the securities class action lawsuit.

Mar 08, 2023 08:15 pm ET

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB

NEW YORK, March 8, 2023 /PRNewswire/ --

Mar 08, 2023 11:57 am ET

Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice: Robbins LLP Urges Shareholders to Contact the Firm for Information Regarding Their Rights

The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, for violations...

Mar 08, 2023 04:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Y-mAbs Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 20, 2023 - (NASDAQ: YMAB)

NEW YORK, March 8, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Y-mAbs Therapeutics, Inc..

Mar 07, 2023 09:52 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsui

Mar 07, 2023 12:00 pm ET

DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Mar 07, 2023 12:00 am ET

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That Securities Class Action Lawsuits Have Been Filed on Behalf of Investors in Fate Therapeutics Inc. (FATE), National Vision Holdings, Inc. (EYE

The law firm of Kirby McInerney LLP reminds investors that securities class action lawsuits have been filed on behalf of investors in securities of Fate Therapeutics Inc., National Vision Holdings, Inc., PLDT Inc., and Y-mAbs Therapeutics, Inc....

Mar 06, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Southwest Airlines, Y-mAbs, Bioventus, and ESS and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Southwest Airlines Co. (NYSE: LUV), Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB),...

Mar 06, 2023 04:01 pm ET

YMAB 2-WEEK DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action

Mar 06, 2023 11:50 am ET

DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Mar 06, 2023 11:00 am ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Mar 06, 2023 01:45 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Mar 04, 2023 10:00 am ET

YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

Mar 01, 2023 10:38 pm ET

FILING DEADLINE – Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Y-mAbs Therapeutics, Inc. – YMAB

Mar 01, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Mar 01, 2023 02:10 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Mar 01, 2023 01:00 pm ET

DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Feb 28, 2023 10:56 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB

Feb 28, 2023 12:15 pm ET

DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Feb 28, 2023 10:00 am ET

YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

Feb 27, 2023 05:07 pm ET

YMAB SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Class Action Filed

Feb 27, 2023 03:30 pm ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Feb 27, 2023 11:00 am ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Feb 27, 2023 04:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK, Feb. 27, 2023 /PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders:

Feb 25, 2023 06:00 am ET

Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

NEW YORK, Feb. 25, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) and reminds investors of the March 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Feb 24, 2023 09:50 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB

NEW ORLEANS, Feb. 24, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 20, 2023 to file lead plaintiff applications in a securities class action lawsuit against Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company's securities between October 6, 2020 and October 28, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

Feb 24, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Feb 24, 2023 12:00 pm ET

YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit

BENSALEM, Pa., Feb. 24, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB).

Feb 23, 2023 06:54 pm ET

SHAREHOLDER UPDATE: Y-mAbs Therapeutics, Bioventus Inc, Fate Therapeutics, Inc, and Invivyd Inc: Johnson Fistel Encourages Shareholders to Seek Counsel for Class Action Lawsuits

Shareholder rights law firm Johnson Fistel, LLP announces that class action lawsuits have commenced on behalf of investors of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Bioventus Inc. (NASDAQ: BVS), and Fate Therapeutics, Inc. (NASDAQ: FATE), and...

Feb 23, 2023 04:49 pm ET

ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB

NEW YORK, Feb. 23, 2023 /PRNewswire/ --

Feb 23, 2023 11:00 am ET

DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Feb 22, 2023 11:49 am ET

DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Feb 22, 2023 10:00 am ET

YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

Feb 21, 2023 10:09 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsui

Feb 21, 2023 11:32 am ET

YMAB LOSS ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB

Feb 21, 2023 04:45 am ET

YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on Behalf of Y-mAbs Therapeutics, Inc. Shareholders

NEW YORK, Feb. 21, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) alleging that the Company violated federal securities laws.

Feb 20, 2023 05:56 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Feb 20, 2023 10:04 am ET

YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Filed

Feb 19, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Southwest Airlines, Y-mAbs, Bioventus, and ESS and Encourages Investors to Contact the Firm

Feb 18, 2023 10:00 am ET

Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

NEW YORK, Feb. 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) and reminds investors of the March 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Feb 17, 2023 12:00 pm ET

YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit

LOS ANGELES, Feb. 17, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB).

Feb 16, 2023 07:06 pm ET

Y-mAbs Therapeutics, Inc.: Please contact the Portnoy Law Firm to recover your losses; March 20, 2023 deadline

Feb 16, 2023 03:33 pm ET

YMAB LOSS ALERT: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB

NEW YORK, Feb. 16, 2023 /PRNewswire/ --

Feb 16, 2023 10:00 am ET

DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Feb 16, 2023 10:00 am ET

YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

Feb 15, 2023 10:51 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Y-mAbs Therapeutics, Inc. - YMAB

Feb 15, 2023 12:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Feb 14, 2023 10:50 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB

Feb 14, 2023 07:13 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Feb 14, 2023 12:45 pm ET

DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Feb 14, 2023 07:00 am ET

Y-mAbs Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for

LEAD PLAINTIFF DEADLINE IS MARCH 20, 2023

Feb 14, 2023 04:45 am ET

YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on Behalf of Y-mAbs Therapeutics, Inc. Shareholders

NEW YORK, Feb. 14, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) alleging that the Company violated federal securities laws.

Feb 14, 2023 01:45 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Feb 13, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Feb 13, 2023 08:25 pm ET

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB

Feb 13, 2023 11:30 am ET

YMAB LAWSUIT ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending

Feb 13, 2023 07:40 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Feb 13, 2023 04:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders:

Feb 11, 2023 06:00 am ET

Y-MABS SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

NEW YORK, Feb. 11, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) and reminds investors of the March 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Feb 10, 2023 09:50 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB

NEW ORLEANS, Feb. 10, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 20, 2023 to file lead plaintiff applications in a securities class action lawsuit against Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company's securities between October 6, 2020 and October 28, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

Feb 10, 2023 01:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Feb 10, 2023 04:45 am ET

YMAB SHAREHOLDER ALERT: Jakubowitz Law Reminds Y-mAbs Shareholders of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK, Feb. 10, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB).

Feb 09, 2023 10:37 pm ET

ROSEN, LEADING INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB

NEW YORK, Feb. 9, 2023 /PRNewswire/ --

Feb 09, 2023 03:04 pm ET

Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice: Robbins LLP Urges Shareholders to Contact the Firm for Information Regarding Their Rights

Feb 09, 2023 10:00 am ET

YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

Feb 09, 2023 04:45 am ET

YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities lawsuit.

Feb 08, 2023 09:50 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Y-mAbs Therapeutics, Inc. - YMAB

CEDARHURST, N.Y., Feb. 8, 2023 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company's securities between October 6, 2020 and October 28, 2022, inclusive (the "Class Period"), including shares of Rodgers Silicon prior to July 15, 2021. Shareholders have until March 20, 2023 to file lead plaintiff applications in the securities class action lawsuit.

Feb 08, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioLineRx Ltd. (NASDAQ: BLRX), Enovix Corporation (NASDAQ: ENVX), Southwest...

Feb 08, 2023 07:44 pm ET

YMAB LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB

Feb 08, 2023 12:15 pm ET

DEADLINE ALERT for LUV, GWH, BVS, and YMAB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Feb 08, 2023 12:00 pm ET

YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit

BENSALEM, Pa., Feb. 8, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB).

Feb 08, 2023 11:30 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Did you lose money on investments in Y-mAbs Therapeutics? If so, please visit Y-mAbs Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Joseph R. Seidman, Jr. at (877) 779-1414 or [email protected] to discuss your rights.

Feb 08, 2023 04:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Y-mAbs Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 20, 2023 - (NASDAQ: YMAB)

NEW YORK, Feb. 8, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Y-mAbs Therapeutics, Inc..

Feb 07, 2023 10:49 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsui

Feb 07, 2023 12:00 pm ET

DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Feb 07, 2023 10:56 am ET

Class Action Deadlines: Y-mAbs Therapeutics, Bioventus Inc, Fate Therapeutics, Inc, and Invivyd Inc – Contact Johnson Fistel

Feb 07, 2023 04:45 am ET

YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on Behalf of Y-mAbs Therapeutics, Inc. Shareholders

NEW YORK, Feb. 7, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) alleging that the Company violated federal securities laws.

Feb 07, 2023 01:45 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Feb 06, 2023 09:19 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Feb 06, 2023 03:56 pm ET

YMAB FRAUD ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Filed

Feb 06, 2023 11:00 am ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Feb 04, 2023 10:07 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Feb 04, 2023 06:00 am ET

Y-MABS SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

NEW YORK, Feb. 4, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) and reminds investors of the March 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Feb 03, 2023 09:50 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsui

NEW ORLEANS, Feb. 3, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 20, 2023 to file lead plaintiff applications in a securities class action lawsuit against Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company's securities between October 6, 2020 and October 28, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

Feb 03, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm

Feb 03, 2023 12:00 pm ET

YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit

LOS ANGELES, Feb. 3, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB).

Feb 03, 2023 04:45 am ET

YMAB SHAREHOLDER ALERT: Jakubowitz Law Reminds Y-mAbs Shareholders of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB).

Feb 02, 2023 03:22 pm ET

Y-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Lead Plaintiff Deadline in Class Action Against Y-mAbs Therapeutics, Inc.

Feb 02, 2023 12:11 pm ET

DEADLINE ALERT for LUV, GWH, BVS, and YMAB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Feb 02, 2023 10:37 am ET

YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

Feb 02, 2023 09:00 am ET

Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

Feb 02, 2023 04:45 am ET

YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Feb. 2, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities lawsuit.

Feb 01, 2023 09:50 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Y-mAbs Therapeutics, Inc. - YMAB

CEDARHURST, N.Y. , Feb. 1, 2023 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company's securities between October 6, 2020 and October 28, 2022, inclusive (the "Class Period"), including shares of Rodgers Silicon prior to July 15, 2021. Shareholders have until March 20, 2023 to file lead plaintiff applications in the securities class action lawsuit.

Feb 01, 2023 06:23 pm ET

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors and Encourages Investors to Contact the Firm Before March 20, 2

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Y-mAbs Therapeutics, Inc. (“Y-mAbs”) (NASDAQ: YMAB) securities during the period from October 6, 2020 through October 28, 2022 (the “Class Period”). Inve

Feb 01, 2023 04:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Y-mAbs Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 20, 2023 - (NASDAQ: YMAB)

NEW YORK, Feb. 1, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Y-mAbs Therapeutics, Inc..

Feb 01, 2023 12:45 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Jan 31, 2023 10:57 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB

Jan 31, 2023 02:43 pm ET

DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Jan 31, 2023 04:45 am ET

YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on Behalf of Y-mAbs Therapeutics, Inc. Shareholders

NEW YORK, Jan. 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) alleging that the Company violated federal securities laws.

Jan 31, 2023 01:45 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Jan 30, 2023 05:15 pm ET

ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB

NEW YORK, Jan. 30, 2023 /PRNewswire/ --

Jan 30, 2023 03:28 pm ET

YMAB ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Filed

Jan 30, 2023 11:00 am ET

Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Y-mAbs securities between October 6, 2020 and October 28, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:

Jan 30, 2023 07:00 am ET

Y-mAbs Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for

LEAD PLAINTIFF DEADLINE IS MARCH 20, 2023

Jan 30, 2023 04:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders:

Jan 29, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm

Jan 29, 2023 03:36 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB

Jan 28, 2023 12:05 pm ET

DEADLINE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - YMAB

SAN DIEGO, Jan. 28, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock on the open market, or pursuant to Registration Statements filed with the U.S. Securities and Exchange Commission ("SEC"), between October 6, 2020 and October 28, 2022, inclusive (the "Class Period") have until March 20, 2023 to seek appointment as lead plaintiff. Captioned Corwin v. Y-mAbs Therapeutics, Inc., No. 23-cv-00431 (S.D.N.Y.), the Y-mAbs class action lawsuit charges Y-mAbs as well as certain of its top exec

Jan 27, 2023 09:50 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB

NEW ORLEANS, Jan. 27, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 20, 2023 to file lead plaintiff applications in a securities class action lawsuit against Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company's securities between October 6, 2020 and October 28, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

Jan 27, 2023 03:47 pm ET

Y-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against Y-mAbs Therapeutics, Inc.

Jan 27, 2023 02:33 pm ET

DEADLINE ALERT for YMAB, FATE, and SHC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Jan 27, 2023 04:45 am ET

YMAB SHAREHOLDER ALERT: Jakubowitz Law Reminds Y-mAbs Shareholders of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK, Jan. 27, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB).

Jan 27, 2023 12:45 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Jan 26, 2023 11:00 am ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Jan 26, 2023 04:45 am ET

YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities lawsuit.

Jan 26, 2023 01:45 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit A

Jan 25, 2023 12:00 pm ET

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Law Offices of Howard G. Smith reminds investors of the upcoming March 20, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”).

Jan 25, 2023 04:45 am ET

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Y-mAbs Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 20, 2023 - (NASDAQ: YMAB)

NEW YORK, January 25, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Y-mAbs Therapeutics, Inc.

Jan 24, 2023 10:13 pm ET

Y-MABS THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsui

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 20, 2023 to file lead plaintiff applications in a securities class action lawsuit against Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB), if they purchased the Company’s securities between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Jan 24, 2023 06:33 pm ET

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors and Encourages Investors to Contact the Firm Before March 20, 2

Jan 24, 2023 02:38 pm ET

YMAB DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys Before Application Deadline in Sec

Jan 24, 2023 02:31 pm ET

Y-mAbs Therapeutics, Inc. (YMAB) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Y-mAbs Therapeutics, Inc.

Jan 24, 2023 01:00 pm ET

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ:

Jan 24, 2023 09:01 am ET

NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMAB

Robbins Geller Rudman & Dowd LLP announces that purchasers of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock on the open market, or pursuant to Registration Statements filed with the U.S. Securities and Exchange Commission (“SEC”), between October 6, 202

Jan 24, 2023 04:45 am ET

YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on Behalf of Y-mAbs Therapeutics, Inc. Shareholders

NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) alleging that the Company violated federal securities laws.

Jan 23, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm

Jan 23, 2023 04:51 pm ET

Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

NEW YORK, Jan. 23, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) and reminds investors of the March 20, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Jan 23, 2023 12:00 pm ET

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics (YMAB) Investors

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ:

Jan 23, 2023 11:00 am ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”). Y-mAbs investors have until March 20, 2023 to file a le

Jan 23, 2023 09:30 am ET

SHAREHOLDER ALERT: Barrack, Rodos & Bacine Encourages Y-mAbs Therapeutics Inc. (YMAB) Shareholders to Contact the Firm About a Recently Filed Securities Class Action Lawsuit

Barrack, Rodos & Bacine notifies investors that a securities class action lawsuit has been filed on behalf of purchasers of the common stock of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) (“Y-mAbs”) from October 6, 2020 through October 28, 2022 (the...

Jan 23, 2023 09:00 am ET

Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate

NEW YORK, Jan. 23, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Y-mAbs securities between October 6, 2020 and October 28, 2022, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ymab.

Jan 23, 2023 04:45 am ET

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK, Jan. 23, 2023 /PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders:

Jan 22, 2023 05:39 pm ET

Y-mAbs Therapeutics, Inc.: Please contact the Portnoy Law Firm to recover your losses; March 20, 2023 deadline

The Portnoy Law Firm advises Y-mAbs Therapeutics, Inc. (“Y-mAbs” or “the Company”) (NASDAQ: YMAB) investors that a lawsuit filed on behalf of investors that purchased Y-mAbs securities (NASDAQ: YMAB) October 6, 2020 and October 28, 2022, inclusive...

Jan 22, 2023 02:15 pm ET

YMAB INVESTOR NOTICE: Robbins Geller Rudman & Dowd Announces that Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMAB

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock on the open market, or pursuant to Registration Statements filed with the U.S. Securities and Exchange Commission...

Jan 22, 2023 07:00 am ET

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. (NASDA

Jan 20, 2023 07:15 pm ET

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB

NEW YORK, Jan. 20, 2023 /PRNewswire/ --

You are here

Y-mAbs Therapeutics Inc (OQ:YMAB)

Business Focus: Bio Therapeutic Drugs